News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Toggle Summary Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
SAN DIEGO , May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
SAN DIEGO , May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Toggle Summary Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Toggle Summary US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC ( US WorldMeds ), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S.
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC ( US WorldMeds ), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S.
Toggle Summary Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
SAN DIEGO , March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
SAN DIEGO , March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor
Toggle Summary Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Tempol Reduced Lung Inflammation After High Dose Challenge SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston,
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Tempol Reduced Lung Inflammation After High Dose Challenge SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston,
Toggle Summary Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
SAN DIEGO , March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level.
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
SAN DIEGO , March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level.
Toggle Summary Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that on March 11, 2022 , the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that on March 11, 2022 , the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3
Toggle Summary Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
SAN DIEGO , March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams , effective April 15, 2022 . “Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
SAN DIEGO , March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams , effective April 15, 2022 . “Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided
Toggle Summary Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo
Toggle Summary Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Toggle Summary Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now
Toggle Summary Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
SAN DIEGO , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
SAN DIEGO , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.
Toggle Summary Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Drug overdoses are the leading cause of death for those under age 50 SAN DIEGO , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Drug overdoses are the leading cause of death for those under age 50 SAN DIEGO , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is
Toggle Summary Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
SAN DIEGO , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
SAN DIEGO , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the
Toggle Summary Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Toggle Summary Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
SAN DIEGO , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
SAN DIEGO , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Toggle Summary Adamis Receives FDA Approval for ZIMHI
New High-Dose Naloxone Product for the Treatment of Opioid Overdose SAN DIEGO , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL
Adamis Receives FDA Approval for ZIMHI
New High-Dose Naloxone Product for the Treatment of Opioid Overdose SAN DIEGO , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL
Toggle Summary Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization SAN DIEGO , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the appointment of Meera J. Desai , Ph.D., as a new director and member of
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization SAN DIEGO , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the appointment of Meera J. Desai , Ph.D., as a new director and member of
Toggle Summary Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
Toggle Summary Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.
Toggle Summary Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer
Toggle Summary Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 SAN DIEGO , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 SAN DIEGO , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment
Toggle Summary Adamis Announces Agreement to Sell Portion of US Compounding Business
Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a
Adamis Announces Agreement to Sell Portion of US Compounding Business
Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a
Toggle Summary Adamis Announces Results of 2021 Annual Meeting of Stockholders
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector
Adamis Announces Results of 2021 Annual Meeting of Stockholders
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector